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tant to ensure high compliance and reduce risk of late compli-
cations. The objective of this study was to develop and validate
a satisfaction questionnaire for adults with type-2 diabetes
treated with oral antihyperglycemic agents. METHODS: The
DIAPASON questionnaire was developed in French following a
literature review and in depth interviews among 10 NIDDM
adults and eight experts. The questionnaire was tested among 5
type-2 diabetes patients to verify it’s comprehension, acceptabil-
ity and relevance. Psychometric properties were assessed in
France on a cross-sectional sample of 441 NIDDM participants
recruited by clinicians’, a diabetes patient association and a
health care network. Test-retest reliability was evaluated in a
sub-sample of 84 clinically stable type two diabetes participants.
RESULTS: Using principal component analysis, four scales were
identiﬁed: Nutrition (nine items), Physician (three items), Atti-
tudes toward diabetes (ﬁve items), and Medication (ﬁve items).
Item convergent and item discriminant validity were satisfactory.
Cronbach’s alphas ranged from 0.67 to 0.87 providing evidence
of internal consistency. Intraclass correlation coefﬁcients
exceeded 0.70 for all scales except for Medication (0.57). Sig-
niﬁcant between-group differences were found demonstrating
the known groups validity of the questionnaire. Men were more
satisﬁed than women in regards to Attitudes (p = 0.0004) and
Medication (p = 0.0037). Subjects with shorter diabetes duration
were less satisﬁed with Nutrition (p < 0.0001) but had more pos-
itive Attitudes (p = 0.0432) than the others. Participants
recruited by the health care network were more satisﬁed with
their Physician (p = 0.0002) than the other patients. CONCLU-
SIONS: The DIAPASON is a valid and reliable questionnaire
measuring the degree of satisfaction of adults with type-2 dia-
betes treated with oral antihyperglycemic agents. This question-
naire may be used in different settings to evaluate and to identify
aspects of health care in need of improvement.
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OBJECTIVES: On the basis of evidence suggesting similar effec-
tiveness between SSRIs and tricyclics, this study sought to esti-
mate the relative cost-effectiveness of policies to offer SSRIs,
tricyclics and lofepramine as ﬁrst-line treatment for depression
using two alternative measures of effect. METHODS: Patients
attending primary care were randomised to receive an SSRI, tri-
cyclic or lofepramine. Patients were allowed to switch between
treatment arms. An NHS and social care perspective was
assumed. Resource-use information over one year was obtained
from GP records. The Hospital Anxiety and Depression Scale
and the EQ-5D were administered at speciﬁed time points, and
used to estimate depression-free weeks (DFW) and QALYs.
Incremental cost-effectiveness ratios were calculated and cost-
effectiveness acceptability curves used to reﬂect uncertainty. The
data were analysed on an intent-to-treat basis. RESULTS: A total
of 109, 113 and 105 patients were randomised to receive a SSRI,
tricyclic and Lofepramine respectively. The economic analysis
was conducted for 264 patients for whom health outcome data
were available. The mean incremental cost-per-DFW for patients
randomised to SSRIs was £59 compared to lofepramine and £32
compared to tricyclics. The mean incremental cost per DFW of
tricyclics was £183 compared to lofepramine. The mean incre-
mental cost-per-QALY for patients randomised to SSRIs was
£5686 compared to lofepramine and £2692 compared to tri-
cyclics. Relative to lofepramine, the tricyclic group had margin-
ally fewer QALYs and higher costs. CONCLUSIONS: The
results from the cost-per-QALY analysis suggest that SSRIs
provide a small additional beneﬁt at an acceptable cost.
However, when analysed using DFWs, the results suggest that
SSRIs will only be the most cost-effective treatment option if
decision-makers are prepared to pay an extra £50 per DFW.
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OBJECTIVES: Reimbursement of a new drug often depends on
its budgetary impact. Identifying the budget impact of a new
drug introduction requires characterizing the evolution of the
costs related to competing drugs. We present, in the context of
schizophrenia, a simple model to estimate the evolution of pre-
scriptions if no other drug is added to those already reimbursed.
This model allows for a probabilistic sensitivity analysis.
METHODS: A cross sectional survey was conducted among a
sample of ambulatory and hospital psychiatrists. Data was col-
lected for 1855 patients about treatment changes in the past 12
months. We use this data to estimate a Markov transition matrix
and characterize uncertainty about the estimates using Dirichlet
distributions. The Markov model is then tailored to allow entries
and exits from the population. Market share is then computed
for the next three years, a Monte Carlo simulation is performed
as a sensitivity analysis, and the results are compared to the
antipsychotic sales trends from 1998 to 2003. RESULTS: Second
generation antipsychotics (SGAs) prescriptions are expected to
increase in the next years. Their market share should grow from
62% to 70% three years later. This increase is explained by a
rising importance of olanzapine and risperidone prescriptions.
These estimations are consistent with the observed sales trends,
the model trends differing from the observed sales end out to be
non signiﬁcant in the sensitivity analysis. Since SGAs cost more
than ﬁrst generation antipsychotics, the average daily treatment
cost (DTC) is expected to increase from 2.25€ to 2.53€. CON-
CLUSION: Without any new drug introduction the average
schizophrenia DTC is expected to increase in parallel with the
SGAs prescriptions. Thus, when assessing the budget impact of
a new drug introduction, not considering this spontaneous trend,
would lead to an overestimation of its potential impact.
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OBJECTIVES: To assign utility values for schizophrenia-related
health states using the Assessment of Quality of Life Question-
naire (AQoL) from two different perspectives: general popula-
tion and caregivers. METHODS: Eight schizophrenia-related
health state scenarios were presented to participants from the
general population and caregivers. The participants explained
how these scenarios would impact on their quality of life using
the AQoL. The caregivers were also asked to value their own
quality of life if they were caring for the person described in the
